BlackRock Fund Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

BlackRock Fund Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.26M	Buy	708,778 +96,547	+16%	+$398K	﹤0.01%	3061
2016 Q3	$2.6M	Buy	612,231 +25,511	+4%	+$82.5K	﹤0.01%	3100
2016 Q2	$1.41M	Buy	586,720 +313,067	+114%	+$1.13M	﹤0.01%	3234
2016 Q1	$1.29M	Sell	273,653 -8,443	-3%	-$32.7K	﹤0.01%	3162
2015 Q4	$1.11M	Buy	282,096 +7,795	+3%	+$35.9K	﹤0.01%	3225
2015 Q3	$1.06M	Sell	274,301 -2,053	-0.7%	-$9.43K	﹤0.01%	3205
2015 Q2	$1.27M	Buy	+276,354	New	+$2.65M	﹤0.01%	3201

Other funds holding AST

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

BlackRock Fund Advisors's AST Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Asterias Biotherapeutics Inc. Series A (AST) stake by 16% in Q4 2016, buying an estimated $398K and bringing the position to 708,778 shares worth $3.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3061.

BlackRock Fund Advisors first reported a position in AST in Q2 2015 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

BlackRock Fund Advisors held 708,778 shares of Asterias Biotherapeutics Inc. Series A worth $3.26M as of Q4 2016.
BlackRock Fund Advisors bought 96,547 Asterias Biotherapeutics Inc. Series A shares in Q4 2016, an estimated $398K.
Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3061 holding.
BlackRock Fund Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and has held it in 7 quarters since.
66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.